Formycon AG Stock
Price
Target price
€25.50
€25.50
-0.970%
-0.25
-0.970%
-
05.12.25 / Tradegate
WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Formycon AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Formycon
sharewise wants to provide you with the best news and tools for Formycon, so we directly link to the best financial data sources.
Financials
News
Formycon Stock: Biotech Firm Launches First Corporate Bond
Formycon, the Munich-based biotech company, is breaking new ground in its financing strategy by issuing its first corporate bond to raise up to €50 million. The four-year unsecured bond, scheduled
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
EQS-News: Ranibizumab Biosimilar Epruvy® launched in Germany
EQS-News: Ranibizumab Biosimilar Epruvy® launched in Germany
EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
EQS-News: Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
EQS-News: Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth